Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
Open Access
- 30 July 2008
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (3) , 473-480
Abstract
We investigated the antitumour effect and ability to overcome the resistance to anti-EGFR drugs of enzastaurin, an inhibitor of VEGFR-dependent PKCβ signalling. Enzastaurin was evaluated alone and in combination with the EGFR inhibitor gefitinib, on growth and signalling protein expression in human cancer cells sensitive and resistant to anti-EGFR drugs, both in vitro and in nude mice. We demonstrated the marked inhibitory activity of enzastaurin against GEO colon and PC3 prostate cancer cells and their gefitinib-resistant counterparts GEO-GR and PC3-GR, accompanied by inhibition of pAkt and its effector pp70S6K, pGSK3β and VEGF expression and secretion. Moreover, enzastaurin showed a cooperative effect with gefitinib in parental and in gefitinib-resistant cells. Remarkably, these results were confirmed in vivo, where enzastaurin showed antitumour activity and cooperativity with gefitinib in mice grafted with GEO and GEO-GR tumours, incrementing their median survival and inhibiting the aforesaid protein expression and secretion in tumour specimens. In conclusion, enzastaurin by interfering with signalling proteins implicated in EGFR drug resistance markedly cooperates with gefitinib in sensitive and gefitinib-resistant tumours, thus overcoming and reverting such resistance and providing a rational basis for its development in patients resistant to anti-EGFR drugs.Keywords
This publication has 35 references indexed in Scilit:
- Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applicationsNature Clinical Practice Oncology, 2008
- A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumorsAnti-Cancer Drugs, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced CancerClinical Cancer Research, 2007
- Synergistic antiglioma activity of radiotherapy and enzastaurinAnnals of Neurology, 2007
- Resistance to epidermal growth factor receptor-targeted therapyDrug Resistance Updates, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Protein Kinase CβII Regulates Its Own Expression in Rat Intestinal Epithelial Cells and the Colonic Epithelium in VivoJournal of Biological Chemistry, 2004
- Identification of Placenta Growth Factor Determinants for Binding and Activation of Flt-1 ReceptorJournal of Biological Chemistry, 2004
- Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsOncogene, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002